TY - JOUR
TI - Perceval S, sutureless aortic valve: cost-consequence analysis
AU - Panagiotopoulos, I.
AU - Kotsopoulos, N.
AU - Verras, G.-I.
AU - Mulita, F.
AU - Katinioti, A.
AU - Koletsis, E.
AU - Triantafyllou, K.
AU - Yfantopoulos, J.
JO - Kardiochirurgia i Torakochirurgia Polska
PY - 2022
VL - 19
TODO - 1
SP - 22-27
PB - Termedia Publishing House Ltd.
SN - null
TODO - 10.5114/kitp.2022.114551
TODO - null
TODO - Introduction: Sutureless aortic valve prostheses have the potential of shortening ischemic time. Aim: We conducted the present study to assess the clinical and economic impact of the biological, sutureless, self-expanding Perceval S valve since the effect of shortened operative times on hospital costs remains unclear. Material and methods: This is a retrospective analysis. From January 2018 to January 2019, 29 patients underwent isolated aortic valve replacement with the Crown PRT bioprosthetic Aortic Valve, whereas 35 patients underwent aortic valve replacement with Perceval S (auto-expanded, sutureless, bioprosthesis). Preoperative data, hospital outcome, and health care resource consumption were compared, using x2 and t-test. Results: Aortic cross-clamp, cardiopulmonary bypass, and operation times were significantly shorter in the Perceval S group (p < 0.001). Patients in the sutureless group required blood transfusion less frequently (p = 0.03) and had a shorter intensive care unit (ICU) stay (p = 0.01). Hospital stay (p = 0.57) and pacemaker implantation were similar between groups. The reduction of aortic cross-clamp, extracorporeal circulation times, and ICU stay resulted in reduced resource consumption in the sutureless group. Conclusions: The use of the Perceval S valve is clinically safe and effective. A shorter procedural time in the sutureless group is associated with better clinical outcomes and reduced hospital costs. © 2022 Termedia Publishing House Ltd.. All rights reserved.
ER -